Giant cell arteritis (GCA) is a chronic inflammatory vasculitis with a significant impact on vascular and patient health. It may present with non-specific symptoms and can lead to severe complications if not managed effectively. This narrative review explores the treatment of GCA with interleukin-6 (IL-6) pathway inhibitors, focusing on key studies from selected databases published between 2018 and 2024. The findings reveal that the current treatment primarily involves glucocorticoids (GCs), but their long-term use is associated with adverse effects. Targeting the IL-6 pathway offers therapeutic benefits by reducing inflammation and sparing GC use. Tocilizumab, a humanized immunoglobulin G1κ monoclonal antibody that blocks the IL-6 receptor, has demonstrated efficacy in achieving sustained remission and improving quality of life in people with GCA. However, challenges remain in understanding the optimal duration of therapy, managing relapse upon discontinuation, and addressing long-term structural vascular outcomes. Additional research is needed to further elucidate the complex pathogenesis of GCA and to optimize treatment strategies to achieve sustained remission both clinically and histologically while minimizing adverse effects. This review provides a comprehensive overview of the evidence of IL-6 inhibition in GCA management, highlighting both its therapeutic benefits and the challenges associated with its use., Competing Interests: Declaration of competing interest Maxime Samson has received remuneration from Chugai (invitation to congresses, remuneration for symposium and consulting payments), AstraZeneca (invitations to congresses, consulting payments), Novartis (research grant, consulting payments, invitation to congresses, remuneration for symposium), CSL Vifor (invitation to congresses, remuneration for symposium and consulting payments), Boehringer Ingelheim (invitation to congresses, consulting payments), Argenx (consulting payments), Fresenius Kabi (consulting payments, invitation to congresses, remuneration for symposium), and GSK (consulting payments, invitation to congresses, remuneration for symposium). Maria C. Cid has acted as a consultant for Glaxo Smith Kline, AbbVie, AstraZeneca, CSL-Vifor, Boehringer Ingelheim, Alexion, and Novartis; received a research grant from Kiniksa Pharmaceuticals Ltd.; and has received funding from Ministerio de Ciencia, Innovación y Universidades, AEI (PID2023-152265OB-I00). Christian Pagnoux reports receiving fees for serving on advisory boards from ChemoCentryx, Otsuka, GlaxoSmithKline, AstraZeneca, Sanofi, and Hoffman-LaRoche; lecture fees from Hoffman-La Roche, GlaxoSmithKline, Otsuka, and CSL Vifor; and educational grant support from Hoffman-La Roche, Otsuka, Pfizer, TEVA, Amgen, and GlaxoSmithKline. Wolfgang A. Schmidt has received consultant fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Fresenius Kabi, GlaxoSmithKline, Novartis, and Sanofi; speaker's bureau fees from AbbVie, Amgen, Bristol Myers Squibb, Chugai, GlaxoSmithKline, Lilly, Johnson & Johnson, Medac, Novartis, Pfizer, Roche, Sanofi, and UCB. He is the principal investigator in trials sponsored by AbbVie, GlaxoSmithKline, Novartis, and Sanofi. Rula A. Hajj-Ali has acted as a consultant for Amgen and GlaxoSmithKline and has received royalties from UpToDate, outside the submitted work. Bhaskar Dasgupta reports grants and personal fees from Roche, and personal fees from GSK, BMS, Sanofi, and AbbVie, outside the submitted work. Anthony Sammel and Carlo Salvarani report no conflict of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)